Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

Stanek,Libor; Springer,Drahomira; Konopasek,Bohuslav; Vocka,Michal; Tesarova,Petra; Syrucek,Martin; Petruzelka,Lubos; Vicha,Ales; Musil,Zdenek

doi:10.3892/ol.2017.7167

Molecular pathological predictive diagnostics in a patient with non‑small cell lung cancer treated with crizotinib therapy: A case report

Authors:
- Libor Stanek
- Drahomira Springer
- Bohuslav Konopasek
- Michal Vocka
- Petra Tesarova
- Martin Syrucek
- Lubos Petruzelka
- Ales Vicha
- Zdenek Musil
View Affiliations

Affiliations: Department of Oncology, First Faculty of Medicine, Charles University in Prague, 12800 Prague 2, Czech Republic, Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, 12800 Prague 2, Czech Republic, Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, 12808 Prague 2, Czech Republic, Department of Pathology, Hospital Homolka, 15030 Prague 5, Czech Republic, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University in Prague, 15006 Prague 5, Czech Republic, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, 12808 Prague 2, Czech Republic
Published online on: October 11, 2017 https://doi.org/10.3892/ol.2017.7167
Pages: 7545-7548

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common malignant cancers in the Czech Republic in men, with the highest mortality rate of all the malignant diseases. The development of biological treatment enables study into novel personalized treatment options. This type of treatment is usually of high quality, and is often demanding of predictive and biopsy diagnostics, which is dependent on the quality of the collected material and close cooperation among particular departments. The present study describes the complete biopsy and predictive examinations performed in a male patient with lung adenocarcinoma, with an emphasis on the logistics of the whole process and the application of the tyrosine kinase inhibitors, crizotinib and LDK378. The patient experienced a long overall survival time of 28 months from diagnosis.

View Figures

View References

1	Zdenek A, Krejčí M and Vorlíček J: Special Oncology. 1st edition. Galen, Prague: pp. 382010
2	Thomas R and Wolf J: Personalized therapy of lung cancer. Onkologie. 35 Suppl 1:S14–S19. 2012. View Article : Google Scholar
3	Li C, Hao L, Li Y, Wang S, Chen H, Zhang L, Ke B, Yin Y, Suo H, Sun B, et al: Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. PLoS One. 9:e1072762014. View Article : Google Scholar : PubMed/NCBI
4	Dundr P, Hornychová H, Matěj R, Ryška A, Staněk L and Tichý T: Guidelines for histological examination of lung carcinoma. Society of Czech Pathologists ČLS JEP. 12–14. 2013.(In Czech).
5	Li Y and Song L: Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 15:106–111. 2012.(In Chinese). PubMed/NCBI
6	Iqbal N and Iqbal N: Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI
7	Ricciardi GR, Russo A, Franchina T, Ferraro G, Zanghì M, Picone A, Scimone A and Adamo V: NSCLC and HER2: Between lights and shadows. J Thorac Oncol. 9:1750–1762. 2014. View Article : Google Scholar : PubMed/NCBI
8	Edge SB, Bryd DR, Compton CC, Fritz AG, Greene FL and Trotti A III: AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: 2009
9	Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE and Varella-Garcia M: Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non small cell lung cancer. Cancer. 118:4486–4494. 2012. View Article : Google Scholar : PubMed/NCBI
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–47. 2009. View Article : Google Scholar : PubMed/NCBI
11	Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat P, Marmey B, Régnard JF, Audouin J and Camilleri-Broët S: Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol. 18:1371–1376. 2005. View Article : Google Scholar : PubMed/NCBI
12	Su YC, Hsu YC and Chai CY: Role of TTF-1, CK20 and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci. 22:14–19. 2006. View Article : Google Scholar : PubMed/NCBI
13	Yatabe Y, Mitsudomi T and Takahashi T: TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 26:767–773. 2002. View Article : Google Scholar : PubMed/NCBI
14	Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C and Chan DC: Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 7:3239–3250. 2001.PubMed/NCBI
15	Roberts PJ, Stinchcombe TE, Der CJ and Socinski MA: Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 28:4769–4777. 2010. View Article : Google Scholar : PubMed/NCBI
16	Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 6:pp. 201–205. 2009, View Article : Google Scholar : PubMed/NCBI
17	Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, et al: Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
18	Marchetti A, Felicioni L, Malatesta S, Sciarrotta Grazia M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F and Buttitta F: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 29:3574–3579. 2011. View Article : Google Scholar : PubMed/NCBI
19	Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, et al: Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the lung cancer mutation consortium. Cancer. 121:448–456. 2015. View Article : Google Scholar : PubMed/NCBI
20	Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
21	Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 4:120ra172012. View Article : Google Scholar : PubMed/NCBI
22	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI